EGFR and brain neoplasm: In the case of brain tumors, a retargeted MV vector with CD46 and signaling lymphocyte activation molecule (SLAM) ablating mutations in the HA protein combined with a single-chain antibody against the epidermal growth factor receptor (EGFR) showed potent antitumor activity against EGFR- or EGFRvIII-overexpressing primary glioblastoma multiforme (GBM) cell lines [79].